TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Clinical Trial Dosing TransCode Therapeutics reports successful initial dosing in its Phase 1a trial. Their novel RNA cancer therapy shows promise with no major safety issues.

TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Clinical Trial Dosing #United_States #Boston #TransCode #TTX-MC138 #RNA_oncology

TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq TransCode Therapeutics has announced a reverse stock split of 1-for-28, aimed at increasing its stock price to meet Nasdaq listing requirements. The split takes effect on May 15, 2025.

TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq #United_States #Stock_Split #Boston #TransCode_Therapeutics #RNA_oncology

TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development TransCode Therapeutics has announced a direct offering to raise funds for cancer research. The offering is set to close on March 25, 2025.

TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development #United_States #Boston #TTX-MC138 #TransCode_Therapeutics #RNA_oncology

TransCode Therapeutics Postpones Special Meeting, Focuses on Shareholder Engagement for Future Votes TransCode Therapeutics has announced the adjournment of its special meeting to February 25, 2025, to gather more shareholder votes on important proposals, emphasizing shareholder participation.

TransCode Therapeutics Postpones Special Meeting, Focuses on Shareholder Engagement for Future Votes #United_States #Boston #Special_Meeting #TransCode_Therapeutics #RNA_oncology

TransCode Therapeutics Successfully Meets Nasdaq Listing Compliance Requirements TransCode Therapeutics has regained Nasdaq compliance with listing requirements, signaling a positive future for its cancer treatment innovations.

TransCode Therapeutics Successfully Meets Nasdaq Listing Compliance Requirements #United_States #NASDAQ #Boston #TransCode_Therapeutics #RNA_oncology